Legal Disclaimer This document is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment
On Wednesday, the Food and Drug Administration issued a warning, calling compounded GLP-1 medications "risky for patients." "FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss," the FDA said
Common Protocols (For Educational Purposes) Note: Always consult a medical professional before beginning any peptide regimen
Aucun effet secondaire grave n'a t signal ce jour
InBody scans measure and track your body fat, visceral fat, lean muscle mass, water weight, and more
Youll also discover why many clients feel results long after their session ends